Dana M. A. Gant

An established clinical researcher with extensive expertise in managing, writing, and executing complex scientific, clinical, and public health research projects. Proficient in research design, data analysis, and leveraging results to develop evidence-based strategies that enhance patient care and health outcomes. Experienced in cross-functional collaboration, regulatory compliance, and leading diverse healthcare research teams.

Masterclass in Scientific Writing and Publishing, Nature

October 2021

Entering Mentoring Training, The University of North Carolina at Chapel Hill (UNC-CH) Graduate School Summer 2021

Organizational Behavior; Leading Teams, American

Public University Winter 2020

Responsible Conduct of Research Certification,

UNC-CH July 2014

Gant DMA, Parris AB, Yang X. Metformin-induced downregulation of c-Met is a determinant of sensitivity in MDA-MB-468 breast cancer cells. Biochem Biophys Res Commun. 2022 Jul 12;613:100-106. doi: 10.1016/j.bbrc.2022.04.139. Epub 2022 May 2. PMID: 35550195.

• C-Met downregulation contributes to Metformin-induced inhibition of MDA-MB-468 triple negative breast cancer cells., 113th Annual Meeting of the AACR, New Orleans, LA, 04/08/22 - 04/13/22
• Results from a Town Hall Meeting: Inflammatory Breast Cancer Listening Session led by KOMEN Scholars., 11th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, New Orleans, LA, 11/02/18 - 11/05/18
• The role of Pim kinases and RUNX transcription factors as potential molecular targets of K-Ras signaling in pancreatic cancer cells., AACR Special Conference on Pancreatic Cancer: Progress and Challenges, Lake Tahoe, NV, 06/18/12 - 06/21/12
• Inhibition of oncogenic Pim Kinases, including Pim-2, alters cell growth and signaling in pancreatic cancer., 103rd Annual Meeting of the AACR, Chicago, IL, 03/31/12 - 04/04/12

• Regulation of c-Met and LRP5 in Metformin Induced Inhibition of Triple Negative Breast Cancer Cells, NCCU, Biological & Biomedical Sciences Department, 04/09/21, Virtual
• COVID-19, Vaccines and Black Medicine Debunked: What we Know Now v. The Tuskegee Experiments, The Prevailing Woman, 01/13/21, Virtual
• The Ultimate Knockout: Breast Cancer Experts, Researchers, and Survivors, Delta Research Education Foundation, 10/21/20, Virtual
• Mechanisms of Metformin Induced c-Met Downregulation in Triple Negative Breast Cancer, Duke Cancer Institute and Duke Clinical Translational Science Institute – Community Advisory Council Meeting, 11/19/19
• Inflammatory Breast Cancer Focus Group, NCCU Komen Graduate Training in Disparities Research (GTDR) Program, 07/17/19, Durham, NC
• Annual Komen GTDR Meeting, NCCU Komen Graduate Training in Disparities Research Program: Building a Trainee-Led Education Program for Inflammatory Breast Cancer, 11th Annual Meeting AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and Medically Underserved, 11/01/18 - 11/02/18, New Orleans, LA
• Komen Young Researchers Roundtable Breakfast, NCCU Komen GTDR Project Overview, 10/15/18, Chapel Hill, NC

• National Institute of Health; F31: Ruth L. Kirschstein Predoctoral Individual National Research Service Award (5F31CA239507-02); September 2019 – September 2022
• American Association for Cancer Research (AACR) – Minorities in Cancer Research Awardee February 2022 (AACR National Conference 2022); New Orleans, LANCCU
• Dean’s List Recognition, 2017 - 2022
• Golden Key International Honor Society, 2010
• Omicron Delta Kappa National Leadership Honor Society, 2008
• GlaxoSmithKline Scholarship Recipient, 2008
• NCCU Foundation Scholarship Recipient, 2007
• African American Network-Duke Energy 3x Scholarship Recipient, 2006-2008
• Phi Eta Sigma National Honor Society, 2006
• Ach-Hughes Black Alumni Association 4x Scholarship Recipient, 2005-2008

• The Black Doctoral Network, 2017 – Present
• American Association for Cancer Research, 2012 – Present
• Delta Sigma Theta Sorority Inc., 2006 - Present